Description
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics. It focused on developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Its product candidate, tovinontrine (IMR-687), tovinontrine is a small-molecule inhibitor of PDE9.